anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-19. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Tibetan Buddhist scholars rely on the north Indian works of scholars such as Asanga, Vasubandhu and Nagarjuna in their interpretation of the 12 nidanas. For example, according to Wayman, Tsongkhapa, attempted to harmonize the presentations of the 12 links found in Nagarjuna and in Asanga. Tsongkhapa also explains how the twelve nidanas can be applied to one life of a single person, two lives of a single person, and three lives of a single person. Discussing the three lifetimes model, Alex Wayman states that the Theravada interpretation is different from the Vajrayana view, because the Vajrayana view places a bardo or an intermediate state (which is denied in Theravada) between death and rebirth. The Tibetan Buddhism tradition allocates the twelve nidanas differently between various lives. Madhyamaka is interpreted in different ways by different traditions. Some scholars accept a version of the shentong view introduced by Dolpopa (1292–1361), which argues that buddha-nature and buddhahood was not dependently originated and thus not empty of itself (but empty of what is not itself). The Gelug school which follows Tsongkhapa's thought rejects this view, and instead holds that all phenomena are said to lack 'inherent' existence (svabhava) and thus, everything is empty and dependently originated. Other Tibetan madhyamakas like Gorampa argue for a more anti-realist view, negating the very existence of all phenomena and seeing them all as illusions.
Active transport is the movement of a substance across a membrane against its concentration gradient. This is usually to accumulate high concentrations of molecules that a cell needs, such as glucose or amino acids. If the process uses chemical energy, such as adenosine triphosphate (ATP), it is called primary active transport. Membrane transport proteins that are driven directly by the hydrolysis of ATP are referred to as ATPase pumps. These types of pumps direct the exergonic hydrolysis of ATP to the unfavorable movement of molecules against their concentration gradient. Examples of ATPase pumps include P-type ATPase's, V-type ATPases, F-type ATPases, and ABC binding cassettes. Secondary active transport involves the use of an electrochemical gradient, and does not use energy produced in the cell. Secondary active transport commonly uses types of carrier proteins, typically symporters and antiporters. Symporter proteins couple the transport of one molecule down its concentration gradient to the transport of another molecule against its concentration gradient, and both molecules diffuse in the same direction. Antiporter proteins transport one molecule down its concentration gradient to transport another molecule against its concentration gradient, but the molecules diffuse in opposite directions. As symporters and antiporters are involved in coupling the transport of two molecules, they are commonly referred to as cotransporters.
Radioactive primordial nuclides found in the Earth are residues from ancient supernova explosions that occurred before the formation of the Solar System. They are the fraction of radionuclides that survived from that time, through the formation of the primordial solar nebula, through planet accretion, and up to the present time. The naturally occurring short-lived radiogenic radionuclides found in today's rocks, are the daughters of those radioactive primordial nuclides. Another minor source of naturally occurring radioactive nuclides are cosmogenic nuclides, that are formed by cosmic ray bombardment of material in the Earth's atmosphere or crust. The decay of the radionuclides in rocks of the Earth's mantle and crust contribute significantly to Earth's internal heat budget.
Sources: en.wikipedia.org
The founding of the Zulu Kingdom was precipitated by the Mfecane, a period of widespread instability and state formation in Southern Africa, caused by pre-existing trends of political centralisation which were catalysed by the effects of international trade, environmental instability, and European colonial expansion.
In the classical pathway, C1 complex recognizes two IgGs or one pentamer IgM, forming an antigen-antibody complex. For the lectin pathway, mannose-binding lectin (MBL) and their associated serine proteins (MASPs), recognize carbohydrates on pathogens, which initiates the C3 convertase C4b2b. The alternative pathway is different due to its spontaneous activation in fluid phase by hydrolysis of C3 to C3(H2O). C3(H2O) can bind to Factor B, which can then be cleaved by the serum protease Factor D, resulting in formation of C3(H2O)Bb. C3(H2O)Bb can cleave additional C3 molecules, creating C3b and C3a.
The general adoption of rotary valves in the place of poppet valves in combustion engines was prevented by the issue of sealing. Poppet valves have a seal around the tapered flange of the opening, and this seal improves with increased working pressure in the combustion chamber because the pressure forces the valve shut. In contrast, rotary valves have to move freely to operate and need to be lubricated with oil, causing issues with holding pressures of up to 100 bar at temperatures of 1000 degrees Celsius, with the related thermal expansion of the various seals and valve barrel. This valve expansion causes misalignment in the valve-to-seal interface as an engine moves from room temperature to full operating temperature. If the seals are pressed against the valve with higher pressure to accommodate this expansion, high friction and power loss occurs, plus high rates of wear. The rotary valve combustion engine possesses several significant advantages over the conventional assemblies, including significantly higher compression ratios and rpm, meaning more power, a much more compact and light-weight cylinder head, and reduced complexity, meaning higher reliability and lower cost. As inlet and exhaust are usually combined, special attention should be given to valve cooling to avoid engine knocking. Rotary valves have been used in several different engine designs. R.A. Reynolds got a patent: US 1002756, 1911, for a Disc Rotary Valve in a 4-Stroke engine.
== See also == Artificial Intelligence Act — 2024 European Union regulation Privacy laws of the United States Use of artificial intelligence by the United States Department of Defense Americans for Responsible Innovation - nonprofit advocacy group
Sources: en.wikipedia.org
=== Withdrawal === Users of hydromorphone may experience painful symptoms if the drug is suspended. Some people cannot tolerate the symptoms, which results in continuous drug use. Symptoms of opioid withdrawal are not easy to decipher, as there are differences between drug-seeking behaviors and true withdrawal effects. Symptoms associated with hydromorphone withdrawal include:
=== ASPIRE trial === A phase III confirmatory clinical trial, known as the ASPIRE trial, compared carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma and found improved progression-free survival and overall survival. Treatment discontinuation because of adverse effects occurred less frequently in the KRd arm, and events included thrombocytopenia, hypertension, and heart failure.
=== Eligibility of minors === While the WPATH standards of care generally require the patient to have reached the age of medical majority, they include a separate section devoted to children and adolescents. Prepubescent children do not have access to medical intervention for gender-affirming therapy. After puberty, some medical intervention is available for adolescents depending on specific criteria for gender incongruence diagnosis, capacity for informed consent, and mental and physical health. According to a study by JAMA Pediatrics published in January 2025, less than 0.1% of adolescents covered by private medical insurance in the US take gender-affirming medication to treat gender dysphoria.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.